Summary of HR 4101 - Cancer Drug Parity Act of 2025

Purpose and Intent

The Cancer Drug Parity Act of 2025 aims to ensure equitable access to cancer treatment by mandating that health insurance plans provide coverage for oral cancer medications on par with intravenous (IV) treatments. This legislation seeks to eliminate the financial disparities that currently exist between these two forms of treatment, thereby improving patient access to necessary medications.

Key Provisions

The bill includes several significant provisions:

• Coverage Equality: Health insurance plans must cover oral cancer drugs at the same cost-sharing levels as IV cancer treatments. This means that patients will not face higher out-of-pocket costs for taking oral medications compared to receiving treatments through infusion.

• Cost Transparency: Insurers will be required to provide clear information regarding the costs associated with both oral and IV cancer treatments, ensuring that patients are fully informed about their financial responsibilities.

• Patient Protections: The bill includes provisions to protect patients from being denied coverage for oral cancer medications based on their treatment plan or the method of administration.

Affected Parties

The primary beneficiaries of the Cancer Drug Parity Act will be:

• Cancer Patients: Individuals diagnosed with cancer who require medication will benefit from reduced financial burdens associated with oral treatments.

• Healthcare Providers: Oncologists and healthcare professionals will have more flexibility in prescribing treatments without the concern of cost disparities affecting patient choices.

• Insurance Companies: Health insurers will need to adjust their coverage policies to comply with the new requirements, potentially leading to changes in their pricing structures.

Legislative Process and Timeline

• Introduced: The bill was introduced in the House on June 24, 2025.

• Referred to Committee: The bill has been referred to the House Committee on Education and Workforce for further consideration.

Conclusion

The Cancer Drug Parity Act of 2025 represents a significant step towards ensuring that all cancer patients have equal access to necessary treatments, regardless of the method of administration. By addressing the financial disparities between oral and IV cancer medications, this legislation aims to improve patient outcomes and enhance the quality of care for those battling cancer.